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Letter to the Editor
High-dose chemotherapy with 
reduced-dose craniospinal radio-
therapy in children with newly 
diagnosed high-risk brain tumor
TO THE EDITOR: A recent report of "Reduced-dose cranio-
spinal radiotherapy followed by high-dose chemotherapy 
and autologous stem cell rescue for children with newly 
diagnosed high-risk medulloblastoma and supratentorial 
primitive neuroectodermal tumor (sPNET)" by Kim et al. 
has shown encouraging results concerning event-free sur-
vival [1]. 
  Reduced dose radiation therapy for children with cancer 
is important because of its effects on intelligence quotient 
and endocrinologic complications. In this study, Kim et 
al. report an event-free survival of 77% for children with 
high-risk medulloblastoma or sPNET, which is comparable 
to other studies, despite having lowered CSI dose to standard 
risk patient level of 23.4 Gy. The major limitations of this 
study are, however, short duration of follow-up and limited 
number of patients enrolled (13 overall), necessitating fur-
ther follow-up of the study cohort.
  Treatment of patients with high-risk medulloblastoma 
or sPNET has yet to reach a consensus, but few doubt the 
importance of adjuvant radiotherapy and chemotherapy af-
ter surgical resection. Radiation therapy ranging from 35-39 
Gy combined with either chemotherapy or high dose che-
motherapy and autologous stem cell transplantation has led 
to progression-free survival of 35-70% [2-4]. However, the 
specific regimen comprising chemotherapy varies considerably.
  High dose chemotherapy and autologous stem cell rescue 
(HDCT and ASCR) are administered in an attempt to max-
imize chemotherapeutic effect. Gajjar et al. reported a 70% 
event-free survival for 48 patients with high-risk medullo-
blastoma after 4 cycles of cyclophosphamide-based HDCT 
and ASCR, emphasizing the efficacy of HDCT for patients 
with chemotherapy-responsive brain tumors [4]. However, 
the amount of cyclophosphamide utilized in this study may 
have resulted in patient infertility, and a similar concern 
should be voiced for potential long-term complications in 
the Korean recipients of tandem transplantation.
  Several other pertinent points should be made; the 2 
patients who relapsed before proceeding to HDCT indicate 
the possible advantages of modifying the current protocol 
in order to shorten the interval between radiotherapy and 
HDCT, or giving due consideration to novel modalities such 
as hyperfractionated radiation therapy or IMRT. Also, the 
2 patients who are surviving event-free despite having un-
dergone only 1 cycle of HDCT and ASCR raise the question 
of the necessity of a second cycle.
  Medulloblastoma itself is a diagnosis that encompasses 
numerous disease entities, and recent research has shed 
some light on the relationship between tumor biology and 
pathology, and overall patient prognosis [5]. With develop-
ments in risk adapted treatment and targeted therapy ac-
cording to diagnostic subgroup, more specific pathologic 
classification and biologic characterization may become im-
perative for future patients receiving similar therapy.
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